Therapeutic advances in hematology · 2025
BEST study: one-year descriptive follow-up of bevacizumab treatment in hereditary haemorrhagic telangiectasia post-BABH interventional study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dupuis-Girod Sophie, Decullier Evelyne, Rivière Sophie, Lavigne Christian, Grobost Vincent, Leguy-Seguin Vanessa, Maillard Hélène, Chinet Thierry, Fargeton Anne-Emmanuelle, Guilhem Alexandre, Hermann Ruben
Аннотация
BACKGROUND: Hereditary haemorrhagic telangiectasia (HHT) is a genetic vascular disorder characterised by telangiectases, which cause nasal and gastrointestinal (GI) bleeding, and visceral arteriovenous malformations. Since 2012 bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, has been a promising treatment for HHT-related bleeding and was evaluated in the phase II BABH study.
OBJECTIVE: To follow and describe evolution and treatments of patients with HHT post-BABH study.
DESIGN: This study is a 1-year, multi-centre descriptive study.
METHODS: We collected clinical (nose and GI bleeding, red blood cell transfusions) and biological (haemoglobin and ferritin levels) data and treatment information.
RESULTS: Of 22 patients included across 4 centers, 15 received bevacizumab. Among them, 12 (86%) had a >50% decrease in the number of RBC units transfused 3 months post-treatment. Mean haemoglobin levels increased from 83.08 to 105.98 g/L.
CONCLUSION: Bevacizumab effectively reduces RBC transfusions and is efficient for treating severe bleeding in patients with HHT.
TRIAL REGISTRATION: This trial was registered with the ClinicalTrials.gov Identifier #NCT06039124.
OBJECTIVE: To follow and describe evolution and treatments of patients with HHT post-BABH study.
DESIGN: This study is a 1-year, multi-centre descriptive study.
METHODS: We collected clinical (nose and GI bleeding, red blood cell transfusions) and biological (haemoglobin and ferritin levels) data and treatment information.
RESULTS: Of 22 patients included across 4 centers, 15 received bevacizumab. Among them, 12 (86%) had a >50% decrease in the number of RBC units transfused 3 months post-treatment. Mean haemoglobin levels increased from 83.08 to 105.98 g/L.
CONCLUSION: Bevacizumab effectively reduces RBC transfusions and is efficient for treating severe bleeding in patients with HHT.
TRIAL REGISTRATION: This trial was registered with the ClinicalTrials.gov Identifier #NCT06039124.